Oncology Pharmacy Clinical Sessions (L259201)

ACPE Numbers: Various – see listing below
Content Release Date: December 17, 2025
Expiration Date: December 15, 2026
Activity Type: Application-based
CE Credits: 4.0 contact hours (ACPE and BPS)
Activity Fee: $160 (ASHP member); $270 (non-member)

Activity Overview

This Clinical Sessions package is intended for board-certified pharmacists in need of recertification credit and is designed based on the content outline developed by the Board of Pharmacy

This Clinical Sessions package is intended for board-certified pharmacists in need of recertification credit and is designed based on the content outline developed by the Board of Pharmacy Specialties (BPS). Using a case-based approach, the activities provide high-level, interactive discussions on contemporary and emerging issues in oncology pharmacy.

The Oncology Pharmacy Clinical Sessions Recertification Package consists of 2 activities (see table below) and provides up to 4.0 contact hours of continuing pharmacy education and/or recertification credit.

These activities are part of the ASHP and ACCP professional development program for BCOP recertification approved by BPS.

These activities were presented as part of the 2025 ACCP Annual Meeting and 2025 ASHP Midyear Clinical Meeting. Learners who claimed ACPE credit for these activities as part of that meeting should not claim ACPE credit again.

Accreditation

The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education with Commendation.

The American College of Clinical Pharmacy is accredited by the Accreditation Council for Pharmacy Education as providers of continuing pharmacy education.

Target Audience

These recertification activities are intended for board certified pharmacists seeking to update their knowledge and skills in:

The background of Ph-like ALL, the current treatment strategies, a resultant health disparity for Latino/Latina patients with ALL, and areas of ongoing and needed research
The incorporation of targeted agents to aid in effectively managing gastrointestinal (GI) malignancies

Recertification Credit

Board-certified pharmacists are eligible to receive up to 4.0 contact hours of recertification credit for completing this course. To earn recertification credit, learners must review the course content and successfully complete the online assessments by the deadline.

ASHP provides an opportunity for remediation. Participants who are unsuccessful with the first assessment attempt may take a second assessment. The second assessment is included at no additional cost.

ACCP and ASHP is approved by BPS as a provider for the recertification of BCOP.

Learning Activity

Passing Score

Credit Information

Philadelphia-Like Acute Lymphoblastic Leukemia: Understanding and Closing a Health Disparity

78%

2.0 Contact Hours

BPS: BCOP
ACPE: 0217-9999-25-152-H01-P

FISHing for Targets: Updates in GI Malignancies

78%

2.0 Contact Hours

BPS: BCOP
ACPE: 0217-9999-25-153-H01-P

Learning Objectives

Philadelphia-Like Acute Lymphoblastic Leukemia: Understanding and Closing a Health Disparity
ACPE: 0217-9999-25-152-H01-P

Discuss the underlying pathophysiology, epidemiology, and diagnostic approach to Acute Lymphoblastic Leukemia.
Compare the treatment outcomes of Ph-like Acute Lymphoblastic Leukemia to other subtypes of Acute Lymphoblastic Leukemia.
Design an evidence-based treatment regimen for a patient with newly diagnosed Ph-like Acute Lymphoblastic Leukemia.
Analyze the disparity in treatment outcomes for Latino/Latina patients with Acute Lymphoblastic Leukemia.
Assess unmet needs and areas of ongoing research for the treatment of Latino/Latina patients with Ph-like Acute Lymphoblastic Leukemia.

This activity is approved for Board-Certified Oncology Pharmacist (BCOP) recertification credit.

FISHing for Targets: Updates in GI Malignancies
ACPE: 0217-9999-25-153-H01-P

Review updates in treatment of GEJ, gastric and colorectal cancers.
Discuss targetable biomarkers within GI malignancies.
Review primary literature for targeted agents recently FDA approved for GI malignancies.
Implement toxicity management strategies for targeted agents recently FDA approved for management of GI malignancies.
Identify appropriate treatments for patients with GI malignancies through patient cases.

This activity is approved for Board-Certified Oncology Pharmacist (BCOP) recertification credit.

Faculty

Faculty bios

Shawn Griffin, PharmD, BCOP
Associate Clinical Professor
University of California, Irvine
Irvine, California

Lydia Benitez Colon, PharmD, BCOP
Adult Outpatient Leukemia Pharmacist & Clinical Associate Professor
University of Michigan College of Pharmacy
Ann Arbor, Michigan

Matthew Peery, PharmD, BCOP*
Hematology/Oncology Clinical Pharmacy Specialist
Virginia Commonwealth University Health
Richmond, Virginia

Amber Cipriani, PharmD, BCOP
Precision Medicine Pharmacy Coordinator / Clinical Associate Professor
University of North Carolina Health / UNC Eshelman School of Pharmacy
Chapel Hill, North Carolina

Lisa Holle, PharmD, BSPharm, BCOP
Associate Professor (CHS)
University of Wisconsin-Madison School of Pharmacy
Madison, Wisconsin

*Content Matter Experts

Editors/Reviewers

Field Testers

Anmar Abdaljalil, BSc Pharmacy BCOP
Janet Bramell, PharmD, BCPS, BCOP
Erika Brown, BS, MS, PharmD, BCOP
Anil Chava, PhD, MS, BS, RPh, BCOP
Allison Cone, PharmD, BCPS, BCOP
Kelley Doherty, PharmD, BCOP, BCPS
Bryna Ewachiw, PharmD, BCOP
Bryan Feagan, PharmD, BCPS, BCACP, BCOP
Sarah Hayes, PharmD, BCOP
Katherine Hill, PharmD, BCOP
Jeff Kaiser, PharmD, BCPS, BCOP
Nirachorn Kuchonthara, PharmD, BCOP, BCNSP
Nicholas Lockhart, PharmD, BCOP
Sundari Poegoah, PharmD, BCOP
Amy Riedel, PharmD, APh, BCPS, BCOP
Emily Viehl Rux, PharmD, BCOP
Hope Schenk, PharmD, BCOP
Emma Sheldon, PharmD, BCOP
Jeffrey Sivik, PharmD, BCOP
Morgan Steiner, PharmD, BCOP
Elizabeth Weddendorf, PharmD, BCPS, BCOP
Olivia White, PharmD, BCOP
Carolnn Yong, PharmD, BCOP

Disclosures

In accordance with our accreditor’s Standards of Integrity and Independence in Accredited Continuing Education, ASHP requires that all individuals in control of content disclose all financial relationships with ineligible companies. An individual has a relevant financial relationship if they have had a financial relationship with an ineligible company in any dollar amount in the past 24 months and the educational content that the individual controls is related to the business lines or products of the ineligible company.

An ineligible company is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The presence or absence of relevant financial relationships will be disclosed to the activity audience.

The following persons in control of this activity’s content have relevant financial relationships:

Lydia Benitez Colon: Contractor – Amgen
Shawn Griffin: Speakers’ Bureau – Geron
Matthew Peery: Advisor – Janssen Pharmaceuticals, Inc.